Income Statement Myriad Genetics, Inc.
Equities
MYGN
US62855J1043
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.39 USD | -1.04% | -16.45% | -9.63% |
Jan. 15 | Myriad Genetics, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 03:45 PM | |
Jan. 15 | Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 851M | 600M | 691M | 678M | 753M | |||||
Total Revenues | 851M | 600M | 691M | 678M | 753M | |||||
Cost of Goods Sold, Total | 201M | 183M | 198M | 202M | 236M | |||||
Gross Profit | 650M | 417M | 493M | 476M | 517M | |||||
Selling General & Admin Expenses, Total | 535M | 514M | 538M | 515M | 567M | |||||
R&D Expenses | 85.9M | 71.6M | 81.9M | 85.4M | 88.7M | |||||
Other Operating Expenses, Total | 621M | 585M | 620M | 600M | 656M | |||||
Operating Income | 29.5M | -169M | -127M | -124M | -139M | |||||
Interest Expense, Total | -12M | -11.6M | -6.6M | -3.2M | -2.9M | |||||
Interest And Investment Income | 3.2M | 1.4M | 700K | 2.6M | 2.5M | |||||
Net Interest Expenses | -8.8M | -10.2M | -5.9M | -600K | -400K | |||||
Currency Exchange Gains (Loss) | - | - | - | - | -3.4M | |||||
Other Non Operating Income (Expenses) | 1.2M | -2.4M | -600K | 600K | 500K | |||||
EBT, Excl. Unusual Items | 21.9M | -181M | -133M | -124M | -142M | |||||
Merger & Related Restructuring Charges | -20.8M | - | - | - | - | |||||
Impairment of Goodwill | - | -82M | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | -1.5M | |||||
Gain (Loss) On Sale Of Assets | - | 1M | 152M | - | - | |||||
Asset Writedown | - | -17.7M | -1.8M | -16.9M | -5.7M | |||||
Legal Settlements | - | - | -62M | - | -113M | |||||
Other Unusual Items | -1.1M | -7M | -11.7M | - | - | |||||
EBT, Incl. Unusual Items | 0 | -188M | -57.1M | -141M | -262M | |||||
Income Tax Expense | -4.4M | -82M | -29.9M | -28.6M | 1.1M | |||||
Earnings From Continuing Operations | 4.4M | -106M | -27.2M | -112M | -263M | |||||
Net Income to Company | 4.4M | -106M | -27.2M | -112M | -263M | |||||
Minority Interest | 200K | 100K | - | - | - | |||||
Net Income - (IS) | 4.6M | -106M | -27.2M | -112M | -263M | |||||
Net Income to Common Incl Extra Items | 4.6M | -106M | -27.2M | -112M | -263M | |||||
Net Income to Common Excl. Extra Items | 4.6M | -106M | -27.2M | -112M | -263M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.06 | -1.42 | -0.35 | -1.39 | -3.18 | |||||
Basic EPS - Continuing Operations | 0.06 | -1.42 | -0.35 | -1.39 | -3.18 | |||||
Basic Weighted Average Shares Outstanding | 73.5M | 75M | 78M | 80.6M | 82.8M | |||||
Net EPS - Diluted | 0.06 | -1.42 | -0.35 | -1.39 | -3.18 | |||||
Diluted EPS - Continuing Operations | 0.06 | -1.42 | -0.35 | -1.39 | -3.18 | |||||
Diluted Weighted Average Shares Outstanding | 76M | 75M | 78M | 80.6M | 82.8M | |||||
Normalized Basic EPS | 0.19 | -1.51 | -1.07 | -0.96 | -1.07 | |||||
Normalized Diluted EPS | 0.18 | -1.51 | -1.07 | -0.96 | -1.07 | |||||
Supplemental Items | ||||||||||
EBITDA | 102M | -97M | -63.9M | -71M | -82.7M | |||||
EBITA | 88.8M | -107M | -76M | -82.6M | -96.1M | |||||
EBIT | 29.5M | -169M | -127M | -124M | -139M | |||||
EBITDAR | 122M | -38.6M | -43.2M | - | -56.8M | |||||
Total Revenues (As Reported) | 851M | 600M | 691M | 678M | 753M | |||||
Effective Tax Rate - (Ratio) | - | 43.57 | 52.36 | 20.34 | -0.42 | |||||
Current Domestic Taxes | -24.3M | -153M | 1.7M | 1.4M | 5.2M | |||||
Current Foreign Taxes | 200K | 400K | 100K | 500K | 200K | |||||
Total Current Taxes | -24.1M | -152M | 1.8M | 1.9M | 5.4M | |||||
Deferred Domestic Taxes | - | 71.4M | - | - | - | |||||
Deferred Foreign Taxes | - | -1M | - | - | - | |||||
Total Deferred Taxes | 19.7M | 70.4M | -31.7M | -30.9M | -4.3M | |||||
Normalized Net Income | 13.89M | -113M | -83.25M | -77.31M | -88.88M | |||||
Interest on Long-Term Debt | 12M | 5.8M | 6.6M | 3.2M | 2.9M | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 85.9M | 71.6M | 81.9M | 85.4M | 88.7M | |||||
Net Rental Expense, Total | 19.7M | 9.9M | 20.7M | - | 25.9M | |||||
Imputed Operating Lease Interest Expense | 15.58M | 6.02M | 5.73M | - | 4.04M | |||||
Imputed Operating Lease Depreciation | 4.12M | 12.38M | 14.97M | - | 21.86M | |||||
Stock-Based Comp., COGS (Total) | 1M | 1.4M | 1.6M | 1.7M | 1.4M | |||||
Stock-Based Comp., R&D Exp. (Total) | 5.4M | 4.8M | 4.2M | 5.2M | 4M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 27.1M | 23.6M | 30.5M | 31.2M | 35.3M | |||||
Total Stock-Based Compensation | 33.5M | 29.8M | 36.3M | 38.1M | 40.7M |